Recursion Pharmaceuticals (RXRX) just moved onto many investors’ radar after Sanofi optioned the first development candidate ...
Recursion Pharmaceuticals reported past pipeline and collaboration progress, including positive REC-4881 and REC-1245 trial ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) surpasses market returns: Some facts worth knowing
Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.66, demonstrating a +1.39% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's ...
Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...
Cathie Wood’s Ark Invest increased its exposure to AI infrastructure, digital platforms, and biotechnology, led by purchases ...
Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other ...
Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Since I called it three times in the recursion, the return process also happens three times. Even though I understood it in ...
ARK Invest sold Twist Bioscience shares and bought Recursion Pharmaceuticals, Intellia Therapeutics, and Veracyte stock on October 5, 2026.
Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results